Should we STOP immunosuppression for IgA nephropathy? Long-term outcomes from the STOP-IgAN trial

Chee Kay Cheung; Jonathan Barratt

doi:10.1016/j.kint.2020.05.033

Should we STOP immunosuppression for IgA nephropathy? Long-term outcomes from the STOP-IgAN trial

Kidney Int. 2020 Oct;98(4):836-838. doi: 10.1016/j.kint.2020.05.033.

Authors

Chee Kay Cheung¹, Jonathan Barratt²

Affiliations

¹ Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UK.
² Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UK. Electronic address: jb81@le.ac.uk.

PMID: 32998815
DOI: 10.1016/j.kint.2020.05.033

Abstract

The role of immunosuppression in the management of IgA nephropathy remains highly controversial. The Supportive Versus Immunosuppressive Therapy for the Treatment of Progressive IgA Nephropathy (STOP-IgAN) trial suggested that there was no benefit with the addition of immunosuppression to intensive supportive care, in terms of renal outcome. In this edition of Kidney International, Rauen et al. report long-term outcomes from the STOP-IgAN trial.

MeSH terms

Glomerular Filtration Rate
Glomerulonephritis, IGA* / drug therapy
Humans
Immune Tolerance
Immunosuppression Therapy
Immunosuppressive Agents / adverse effects

Substances

Immunosuppressive Agents